stay updated with our newsletter

Search
Close this search box.

Echosens Aligns with Fatty Liver Foundation to Accelerate Screening for Undiagnosed Nonalcoholic Fatty Liver Disease

fatty liver

Echosens, a high-technology company offering the FibroScan family of products, is proud to support the Fatty Liver Foundation (FLF), a non-profit organization dedicated to fighting fatty liver disease and advocating for ongoing screening of undiagnosed nonalcoholic fatty liver disease (NAFLD) and its more severe form nonalcoholic steatohepatitis (NASH). FLF isRead

New Diagnostic Tool Diagnoses Early Chronic Kidney Disease and Stops Progression

kidney cancer

Researchers have developed a new test that could diagnose early chronic kidney disease in patients with type 2 diabetes. This novel method, published in AACC’s Clinical Chemistry journal, could improve quality of life for diabetic patients by potentially catching chronic kidney disease in time to stop its progression to full-blownRead

Nonalcoholic Fatty Liver Disease: Thyroid Function and Gut Health as Disease Risk Factors

nonalcoholic fatty liver disease

With increasing rates of obesity and diabetes, the associated condition of nonalcoholic fatty liver disease (NAFLD) has become increasingly common, such that it is now the number one cause of liver disease in Western countries.[1] NAFLD affects 10 to 46% of the U.S. population, with a worldwide prevalence of 10Read

JOIN OUR MAILING LIST

Weekly round-up, access to thought leaders, and articles to help you improve health outcomes and the success of your practice.